Arbutus Biopharma Corporation - Common Stock (ABUS)

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible future actions.

While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.

ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.

Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin

After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.

  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!

Moderna Inc (NASDAQ: MRNA) has 

Here's a roundup of top developments in the biotech space over the last 24 hours:

Here's a roundup of top developments in the biotech space over the last 24 hours:

The company isn't seeking an injunction, but wants "fair compensation."